<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05035030</url>
  </required_header>
  <id_info>
    <org_study_id>A4250-015</org_study_id>
    <nct_id>NCT05035030</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome</brief_title>
  <acronym>ASSERT-EXT</acronym>
  <official_title>An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albireo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albireo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in&#xD;
      Patients with Alagille Syndrome (ASSERT-EXT)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 35 sites will be initiated for this study in North America, Europe, Middle&#xD;
      East, and Asia Pacific.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 3, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pruritus</measure>
    <time_frame>Baseline to week 72</time_frame>
    <description>Change from baseline in scratching score as measured by the Albireo Observer-Reported Outcome Caregiver Instrument</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum bile acids</measure>
    <time_frame>Baseline to week 72</time_frame>
    <description>Change from baseline in serum bile acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>Baseline to week 72</time_frame>
    <description>Change from baseline in quality-of-life assessment as measured by the Pediatric Quality of Life Inventory Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sleep Parameters</measure>
    <time_frame>Baseline to week 72</time_frame>
    <description>Change from baseline in sleep parameters as measured by the Albireo Patient and Observer-Reported Outcome instruments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global Symptom Relief</measure>
    <time_frame>Baseline to Weeks, 4, 12, 24, 48, and 72</time_frame>
    <description>Change from baseline in global symptom relief as measured by both the Global Impression of Symptoms and Global Impression of Change questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Baseline to week 72</time_frame>
    <description>Safety and Tolerability as assessed by the Number of Participants with Treatment-emergent Adverse Events as Assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Alagille Syndrome</condition>
  <arm_group>
    <arm_group_label>Odevixibat (A4250)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules for oral administration once daily for 72 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Odevixibat</intervention_name>
    <description>Odevixibat is a small molecule and selective inhibitor of IBAT.</description>
    <arm_group_label>Odevixibat (A4250)</arm_group_label>
    <other_name>A4250</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Completion of the 24-week Treatment Period of Study A4250-012&#xD;
&#xD;
          2. Signed informed consent and assent as appropriate. Patients who turn 18 years of age&#xD;
             (or legal age per country) during the study will be required to re-consent to remain&#xD;
             on the study&#xD;
&#xD;
          3. Caregivers (and age-appropriate patients) must be willing and able to use an&#xD;
             electronic diary (eDiary) device as required by the study&#xD;
&#xD;
          4. Sexually active males and females must agree to use a reliable contraceptive method&#xD;
             with â‰¤1% failure rate (such as hormonal contraception, intra-uterine device, or&#xD;
             complete abstinence) from signed informed consent through 90 days after last dose of&#xD;
             study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Decompensated liver disease, history or presence of clinically significant ascites,&#xD;
             variceal hemorrhage, and/or encephalopathy&#xD;
&#xD;
          2. Patients who were not compliant with study drug treatment or procedures in Study&#xD;
             A4250-012&#xD;
&#xD;
          3. Any other conditions or abnormalities which, in the opinion of the investigator, may&#xD;
             compromise the safety of the patient, or interfere with the patient participating in&#xD;
             or completing the study&#xD;
&#xD;
          4. Known hypersensitivity to any components of odevixibat&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Childrens Hospital at Montefiore Albert Einstein School of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alagille Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

